Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 30;8(4):e62439.
doi: 10.1371/journal.pone.0062439. Print 2013.

Novel algorithm for non-invasive assessment of fibrosis in NAFLD

Affiliations

Novel algorithm for non-invasive assessment of fibrosis in NAFLD

Jan-Peter Sowa et al. PLoS One. .

Abstract

Introduction: Various conditions of liver disease and the downsides of liver biopsy call for a non-invasive option to assess liver fibrosis. A non-invasive score would be especially useful to identify patients with slow advancing fibrotic processes, as in Non-Alcoholic Fatty Liver Disease (NAFLD), which should undergo histological examination for fibrosis.

Patients/methods: Classic liver serum parameters, hyaluronic acid (HA) and cell death markers of 126 patients undergoing bariatric surgery for morbid obesity were analyzed by machine learning techniques (logistic regression, k-nearest neighbors, linear support vector machines, rule-based systems, decision trees and random forest (RF)). Specificity, sensitivity and accuracy of the evaluated datasets to predict fibrosis were assessed.

Results: None of the single parameters (ALT, AST, M30, M60, HA) did differ significantly between patients with a fibrosis score 1 or 2. However, combining these parameters using RFs reached 79% accuracy in fibrosis prediction with a sensitivity of more than 60% and specificity of 77%. Moreover, RFs identified the cell death markers M30 and M65 as more important for the decision than the classic liver parameters.

Conclusion: On the basis of serum parameters the generation of a fibrosis scoring system seems feasible, even when only marginally fibrotic tissue is available. Prospective evaluation of novel markers, i.e. cell death parameters, should be performed to identify an optimal set of fibrosis predictors.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Prediction performance.
The ROC curve of the RF is shown (p = 0.008). Black dot: performance of the 3 nn (p = 0.02); white circle: performance of the DT (p value = 0.099). The dashed line marks the performance by chance.
Figure 2
Figure 2. Boxplots of the outputs of the RFs.
On the y-axis the predicted class probabilities for stage 1 and stage 2 are plotted. Generally, the RFs give higher prediction values for subjects from stage 1 compared to subjects from stage 2. The upper and the lower quartiles, the median (bold line) as well as outliers (circles) are shown.
Figure 3
Figure 3. Decision Tree.
The decision tree (DT) focuses on the parameters M30, M65 and AST (GOT), which is in partial agreement with the RFs. At the first level, the DT focuses on M30. If the M30 value for a given sample is less than 472.7, it is assigned to the negative class (0). If the M30 value is greater than 472.7, it is transferred to the next level that uses M65. If the M65 value for the given sample is greater than 462.1, it is assigned to the negative class, otherwise it is transferred to the last level. The last level in the DT focuses on GOT. If the GOT value for the given sample is less than 27.5, the sample is assigned as negative, otherwise as a positive sample (1).

References

    1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G (2010) A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53: 372–384. - PubMed
    1. Feldstein AE (2010) Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin. Liver Dis 30: 391–401. - PubMed
    1. Argo CK, Caldwell SH (2009) Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 13: 511–531. - PubMed
    1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313–1321. - PubMed
    1. Grønbaek K, Christensen PB, Hamilton-Dutoit S, Federspiel BH, Hage E, et al. (2002) Interobserver variation in interpretation of serial liver biopsies from patients with chronic hepatitis C. J. Viral Hepat. 9: 443–449. - PubMed

Publication types